Summary: C2N Diagnostics has partnered with Mayo Clinic Laboratories to include its innovative Precivity blood tests, which help detect amyloid plaques associated with Alzheimer’s disease in patients 55 and older, in Mayo Clinic Labs

Takeaways

  1. Enhanced Accessibility: The partnership with Mayo Clinic Laboratories expands the availability of C2N’s Precivity tests, providing healthcare providers with advanced tools to detect Alzheimer’s disease.
  2. Comprehensive Care: Precivity tests aid in identifying amyloid plaques in the brain, a hallmark of Alzheimer’s, and support healthcare providers in making informed medical management and treatment decisions for patients with mild cognitive impairment or dementia.
  3. Commitment to Quality: All Precivity tests are conducted in C2N’s ISO 13485:2016 standard, CAP-accredited, and CLIA-certified laboratory, ensuring high standards of clinical care and diagnostic accuracy.

C2N Diagnostics, which provides exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health, has entered into a non-exclusive agreement with Mayo Clinic Laboratories, for inclusion of C2N’s Precivity tests in Mayo Clinic Laboratories’ test offerings to its clients.

“By offering C2N’s tests to our clients, they have access to a portfolio of Alzheimer’s disease tests to ensure their patients receive the right answers when they need them most,” says William G. Morice II, MD, PhD, president & CEO, Mayo Clinic Laboratories.

Testing for Dementia

The Precivity tests are innovative blood tests intended for use in patients 55 and older with signs or symptoms of mild cognitive impairment or dementia. These tests aid healthcare providers in the detection of amyloid plaques in the brain, a hallmark of Alzheimer’s disease, and help inform medical management and treatment decisions.

“While C2N Diagnostics continues expanding its own commercial, operational and IT infrastructure in the U.S. and strategic countries, we’re extremely pleased to work with Mayo Clinic Laboratories to broaden access to Precivity testing through Mayo Clinic Laboratories’ global distribution channels, extensive U.S. infrastructure and EMR connectivity,” says Joel Braunstein, MD, C2N’s CEO. “This non-exclusive partnership with Mayo Clinic Laboratories builds on our exclusive partnerships in other select markets. Overall, it demonstrates our commitment to excellence in clinical care and to collaborating with premium diagnostics leaders to make high-performance Alzheimer’s disease tests more accessible to healthcare providers and patients around the world. We look forward to elevating the quality of care for many patients in clinical need.”

C2N’s Precivity Tests

The Precivity tests are only available through a healthcare provider’s order. The PrecivityAD2 and PrecivityAD blood tests use highly sensitive and specialized laboratory technologies to identify and measure certain proteins that are found in the blood and that are known to be associated with presence of brain amyloid plaques, the company says.

The main test result is a multiple analyte-derived algorithm score that determines a patient’s likelihood category for the presence of brain amyloid plaques. Like other high-performance tests that evaluate for brain amyloid pathology in clinical patients (such as amyloid PET scan or cerebrospinal fluid testing), the Precivity blood tests by themselves do not diagnose Alzheimer’s disease. Healthcare providers interpret the test results along with other medical information.

All of C2N’s Precivity tests are performed under the ISO 13485:2016 standard and in the company’s CAP accredited, CLIA certified laboratory.